A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes, including liver cancer. Although there is a preventative vaccine and antiviral therapies suppressing HBV replication, there is no cure. Intensive efforts...

Descripción completa

Detalles Bibliográficos
Autores principales: Kramvis, Anna, Chang, Kyong-Mi, Dandri, Maura, Farci, Patrizia, Glebe, Dieter, Hu, Jianming, Janssen, Harry L. A., Lau, Daryl T. Y., Penicaud, Capucine, Pollicino, Teresa, Testoni, Barbara, Van Bömmel, Florian, Andrisani, Ourania, Beumont-Mauviel, Maria, Block, Timothy M., Chan, Henry L. Y., Cloherty, Gavin A., Delaney, William E., Geretti, Anna Maria, Gehring, Adam, Jackson, Kathy, Lenz, Oliver, Maini, Mala K., Miller, Veronica, Protzer, Ulrike, Yang, Jenny C., Yuen, Man-Fung, Zoulim, Fabien, Revill, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Roadmap
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298709/
https://www.ncbi.nlm.nih.gov/pubmed/35859026
http://dx.doi.org/10.1038/s41575-022-00649-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298709/
https://www.ncbi.nlm.nih.gov/pubmed/35859026
http://dx.doi.org/10.1038/s41575-022-00649-z

Ejemplares similares